Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

SIMPLAAFY Clinical Trial

NCT: NCT06521463 · ACTIVE_NOT_RECRUITING

NCT IDNCT06521463
StatusACTIVE_NOT_RECRUITING
Start Date2024-10-01
SponsorBoston Scientific Corporation (INDUSTRY)
First posted
Last updated

Brief Summary

The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑